Aims. Recent preclinical and clinical studies have suggested that baclofen, the prototypic GABAB receptor agonist, is a promising pharmacological compound for the treatment of alcohol dependence. Results. Specifically, baclofen has been found to suppress symptoms of alcohol withdrawal syndrome with an efficacy comparable to that of the ‘gold standard’ diazepam. Moreover baclofen has proven to be effective in the prevention of relapse, likely because of its ability to reduce alcohol intake and craving in alcoholic patients. Baclofen displayed good manageability, as it did not produce any significant side effect. Finally, a recent study extended to alcoholic patients affected by liver cirrhosis the efficacy and safety of baclofen in increasing abstinence rate. Conclusions. Should the above preliminary results be confirmed in larger studies, the efficacy of the drug in the management of both alcohol withdrawal syndrome and relapse prevention should entail a vastly simplified pharmacotherapy of alcohol dependence.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Clinical evidence of the beneficial effects of baclofen in the treatment of alcohol dependence|
|Data di pubblicazione:||2007|
|Tipologia:||1.5 Abstract in rivista|